Sean Parker’s science project breeds a startup
Facebook billionaire Sean Parker has spent the last few years investing his time and money into cancer immunotherapy, and now he’s got a biotech startup to show for it.
As STAT’s Adam Feuerstein reports, ArsenalBio has come into the world with a plan to use newfangled technologies like CRISPR to build improved tumor killers. The company traces its roots to a 2018 retreat hosted by the Parker Institute for Cancer Immunotherapy, where, according to ArsenalBio’s founders, scientists of disparate expertise joined forces to collaborate.
As for the exact focus of that collaboration, we’re a little unclear. According to its founding press release, the company will use “CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm” in immunotherapy. So there’s that.
Read more.
As STAT’s Adam Feuerstein reports, ArsenalBio has come into the world with a plan to use newfangled technologies like CRISPR to build improved tumor killers. The company traces its roots to a 2018 retreat hosted by the Parker Institute for Cancer Immunotherapy, where, according to ArsenalBio’s founders, scientists of disparate expertise joined forces to collaborate.
As for the exact focus of that collaboration, we’re a little unclear. According to its founding press release, the company will use “CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm” in immunotherapy. So there’s that.
Read more.
.png)
No hay comentarios:
Publicar un comentario